# Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

> **NCT05277766** · PHASE1 · RECRUITING · sponsor: **University Hospital, Ghent** · enrollment: 45 (estimated)

## Conditions studied

- Peritoneal Carcinomatosis
- Peritoneal Metastases
- Colorectal Cancer
- Small Bowel Cancer
- Appendix Cancer
- Gastric Cancer
- Pancreatic Cancer
- Bile Duct Cancer

## Interventions

- **DRUG:** PIPAC with Nal-IRI

## Key facts

- **NCT ID:** NCT05277766
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-21
- **Primary completion:** 2026-01
- **Final completion:** 2027-04
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05277766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05277766, "Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05277766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*